A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Who May Qualify: - Age ≥18 years. - You should be able to carry out daily activities with 0 level of ability (ECOG 0) or 1. - diagnosed by tissue sample (biopsy-confirmed): - Clear cell renal cell carcinoma (ccRCC). - Diffuse large B-cell lymphoma (DLBCL, NOS). - High-grade B-cell lymphoma (HGBCL). - Peripheral T-cell lymphoma (PTCL, incl. NOS and ALCL). - Cutaneous T-cell lymphoma (CTCL, incl. MF or SS ≥Stage IIB with B0/B1 blood involvement). - Disease progression, relapse, or refractory to prior therapy: - ccRCC: ≥1 prior line incl. ICI + TKI. - DLBCL/HGBCL: ≥2 prior lines incl. immunochemotherapy and salvage. - PTCL/CTCL: ≥1 previous cancer treatment that works throughout the body (like chemotherapy). - Measurable disease by RECIST v1.1 (ccRCC), Lugano 2014 (lymphomas), or ISCL/USCLC/EORTC (CTCL). - Tumor tissue available for central testing. Who Should NOT Join This Trial: - Untreated or progressive CNS disease unless previously treated and stable. - Other active invasive malignancy within 2 years (except certain low-risk cancers). - Prior CD70-targeting therapy, including CAR T. - ASCT or CAR T ≤12 weeks before enrollment; prior organ or allogeneic transplant. - Unresolved ≥Grade 2 toxicity from prior therapy (with exceptions). - Primary weakened immune system or active autoimmune conditions (where your immune system attacks your own body) requiring immunosuppression. - Active HBV, HCV, HIV, or other chronic infections requiring systemic therapy. - Pregnancy, breastfeeding, or unwillingness to use effective contraception. Other protocol-defined Inclusion/Exclusion Criteria may apply. Always talk to your doctor about whether this trial is right for you.